New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompare5-Amino-1MQ vs Cagrilintide

5-Amino-1MQ vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
5-Amino-1MQ
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
Estimated 4–8 hours
~7–10 days
Admin Route
Oral
SubQ
Research
Typical Dose
50–100 mg
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Once to twice daily
Once weekly
Key Benefits
  • Raises intracellular NAD+ levels
  • Directly targets adipose tissue for fat reduction
  • Reduces fat cell size and differentiation
  • Increases basal metabolic rate
  • SIRT1 activation for metabolic regulation
  • No stimulant cardiovascular side effects
  • Synergistic with intermittent fasting and caloric restriction
  • May have anti-aging metabolic benefits
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Generally well-tolerated in available studies
  • Mild GI discomfort (rare)
  • Limited long-term human data
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With